Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Donald S. Karanewsky is active.

Publication


Featured researches published by Donald S. Karanewsky.


Journal of Biological Chemistry | 1996

Fas-induced activation of the cell death-related protease CPP32 Is inhibited by Bcl-2 and by ICE family protease inhibitors.

Robert C. Armstrong; Teresa Aja; Jialing Xiang; Smita Gaur; Joseph F. Krebs; Kim Hoang; Xu Bai; Stanley J. Korsmeyer; Donald S. Karanewsky; Lawrence C. Fritz; Kevin J. Tomaselli

The human proto-oncogene bcl-2 and its Caenorhabditis elegans homologue ced-9 inhibit programmed cell death. In contrast, members of the human interleukin-1β converting enzyme (ICE) family of cysteine proteases and their C. elegans homologue CED-3 promote the death program. Genetic experiments in C. elegans have shown that ced-9 is formally a negative regulator of ced-3 function, but neither those studies nor others have determined whether CED-9 or Bcl-2 proteins act biochemically upstream or downstream of CED-3/ICE proteases. CPP32, like all known members of the CED-3/ICE family, is synthesized as a proenzyme that is subsequently processed into an active protease with specificity for cleavage at Asp-X peptide bonds. In this report, we demonstrate that the CPP32 proenzyme is proteolytically processed and activated in Jurkat cells induced to die by Fas ligation. CPP32 activation is blocked by cell-permeable inhibitors of aspartate-directed, cysteine proteases, suggesting that pro-CPP32 is cleaved by active CPP32 or by other ICE family members. Heterologous expression of Bcl-2 in Jurkat cells prevents Fas-induced cell death as well as proteolytic processing and activation of CPP32. Thus, Bcl-2 acts at or upstream of the CPP32 activation step to inhibit apoptosis induced by Fas stimulation.


Journal of Biological Chemistry | 1997

Structure of recombinant human CPP32 in complex with the tetrapeptide acetyl-Asp-Val-Ala-Asp fluoromethyl ketone.

Peer R. E. Mittl; S. Di Marco; Joseph F. Krebs; Xu Bai; Donald S. Karanewsky; John P. Priestle; Kevin J. Tomaselli; Markus Grütter

The cysteine protease CPP32 has been expressed in a soluble form in Escherichia coli and purified to >95% purity. The three-dimensional structure of human CPP32 in complex with the irreversible tetrapeptide inhibitor acetyl-Asp-Val-Ala-Asp fluoromethyl ketone was determined by x-ray crystallography at a resolution of 2.3 Å. The asymmetric unit contains a (p17/p12)2 tetramer, in agreement with the tetrameric structure of the protein in solution as determined by dynamic light scattering and size exclusion chromatography. The overall topology of CPP32 is very similar to that of interleukin-1β-converting enzyme (ICE); however, differences exist at the N terminus of the p17 subunit, where the first helix found in ICE is missing in CPP32. A deletion/insertion pattern is responsible for the striking differences observed in the loops around the active site. In addition, the P1 carbonyl of the ketone inhibitor is pointing into the oxyanion hole and forms a hydrogen bond with the peptidic nitrogen of Gly-122, resulting in a different state compared with the tetrahedral intermediate observed in the structure of ICE and CPP32 in complex with an aldehyde inhibitor. The topology of the interface formed by the two p17/p12 heterodimers of CPP32 is different from that of ICE. This results in different orientations of CPP32 heterodimers compared with ICE heterodimers, which could affect substrate recognition. This structural information will be invaluable for the design of small synthetic inhibitors of CPP32 as well as for the design of CPP32 mutants.


Bioorganic & Medicinal Chemistry Letters | 1998

Conformationally constrained inhibitors of caspase-1 (interleukin-1β converting enzyme) and of the human ced-3 homologue caspase-3 (CPP32, apopain)

Donald S. Karanewsky; Xu Bai; Steven D. Linton; Joseph F. Krebs; Joe Wu; Bryan Pham; Kevin J. Tomaselli

A systematic study of interleukin-1 beta converting enzyme (ICE, caspase-1) and caspase-3 (CPP32, apopain) inhibitors incorporating a P2-P3 conformationally constrained dipeptide mimetic is reported. Depending on the nature of the P4 substituent, highly selective inhibitors of both Csp-1 or Csp-3 were obtained.


Bioorganic & Medicinal Chemistry Letters | 2002

Acyl Dipeptides as Reversible Caspase Inhibitors. Part 1: Initial Lead Optimization

Steven D. Linton; Donald S. Karanewsky; Robert J. Ternansky; Joe C. Wu; Brian Pham; Lalitha Kodandapani; Robert Smidt; Jose-Luis Diaz; Lawrence C. Fritz; Kevin J. Tomaselli

Parallel synthesis was used to explore the SAR of a peptidomimetic caspase inhibitor. The most potent compound had nanomolar activity against caspases 1, 3, 6, 7, and 8.


Bioorganic & Medicinal Chemistry Letters | 2003

Structure–Activity relationships within a series of caspase inhibitors: effect of leaving group modifications

Brett R. Ullman; Teresa Aja; Thomas L. Deckwerth; Jose-Luis Diaz; Julia Herrmann; Vincent J. Kalish; Donald S. Karanewsky; Steven P. Meduna; Kip Nalley; Edward D. Robinson; Silvio Roggo; Robert O. Sayers; Albert Schmitz; Robert J. Ternansky; Kevin J. Tomaselli; Joe C. Wu

Various aryloxy methyl ketones of the 1-naphthyloxyacetyl-Val-Asp backbone have been prepared. A systematic study of their structure-activity relationship (SAR) related to caspases 1, 3, 6, and 8 is reported. Highly potent irreversible broad-spectrum caspase inhibitors have been identified. Their efficacy in cellular models of cell death and inflammation are also discussed.


Bioorganic & Medicinal Chemistry Letters | 2002

Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization

Steven D. Linton; Donald S. Karanewsky; Robert J. Ternansky; Ning Chen; Xian Guo; Kathy G. Jahangiri; Vincent J. Kalish; Steven P. Meduna; Edward D. Robinson; Brett R. Ullman; Joe C. Wu; Brian Pham; Lalitha Kodandapani; Robert Smidt; Jose-Luis Diaz; Lawrence C. Fritz; U. von Krosigk; Silvio Roggo; Albert Schmitz; Kevin J. Tomaselli

A new structural class of broad spectrum caspase inhibitors was optimized for its activity against caspases 1, 3, 6, 7, and 8. The most potent compound had low nanomolar broad spectrum activity, in particular, single digit nanomolar inhibitory activity against caspase 8.


The Journal of Neuroscience | 1997

Activation of the CED3/ICE-Related Protease CPP32 in Cerebellar Granule Neurons Undergoing Apoptosis But Not Necrosis

Robert C. Armstrong; Teresa Aja; Kim Hoang; Shikha Gaur; Xiao-hui Bai; Emad S. Alnemri; Gerald Litwack; Donald S. Karanewsky; Lawrence C. Fritz; Kevin J. Tomaselli


Journal of Cell Biology | 1999

Activation of Membrane-associated Procaspase-3 Is Regulated by Bcl-2

Joseph F. Krebs; Robert C. Armstrong; Anu Srinivasan; Teresa Aja; Angela M. Wong; Aileen Aboy; Rob Sayers; Bryan Pham; Tam Vu; Kim Hoang; Donald S. Karanewsky; Christian Leist; Albert Schmitz; Joe C. Wu; Kevin J. Tomaselli; Lawrence C. Fritz


Archive | 1997

C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

Donald S. Karanewsky; Xu Bai


Archive | 1999

C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases

Donald S. Karanewsky; Robert J. Ternansky

Collaboration


Dive into the Donald S. Karanewsky's collaboration.

Researchain Logo
Decentralizing Knowledge